

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**ELECTION OF THE FOURTH SESSION OF
THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS
RETIREMENT OF NON-EXECUTIVE DIRECTOR
AND INDEPENDENT NON-EXECUTIVE DIRECTORS
APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Reference is also made to the circular and overseas regulatory announcement dated 30 May 2024.

ELECTION OF THE FOURTH SESSION OF THE BOARD OF DIRECTORS

The term of office of the third session of the board (the “**Board of Directors**”) of directors (the “**Directors**”) of the Company has expired on the conclusion of the 2023 annual general meeting of the Company (the “**AGM**”) held on 21 June 2024. The Board of Directors is pleased to announce that all proposed Directors have been elected at the AGM and will constitute the fourth session of the Board of Directors. The term of office of Mr. Zhang Chun, an independent non-executive Director, shall commence from the date of the AGM until the date of serving as an independent non-executive Director of the Company for six consecutive years (18 June 2026), and the term of office of the remaining Directors shall be three years with effect from the date of the AGM until the conclusion of the fourth session of the Board of Directors. The fourth session of the Board of Directors comprises (i) Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; (ii) Mr. Tang Yi as a non-executive Director; and (iii) Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, Dr. Shen Jinggang and Dr. Yang Yue as independent non-executive Directors. Further details are set out in the Company’s poll results announcement dated 21 June 2024 and biographical details of the Directors are set out in the Company’s circular dated 30 May 2024.

At the first meeting of the fourth session of the Board of Directors held on 21 June 2024 (the “**Board Meeting**”), Mr. Xiong Jun and Dr. Li Ning were elected as the chairman and vice chairman of the fourth session of the Board of Directors respectively with a term of office for three years with effect from the date of the Board Meeting until the conclusion of the fourth session of the Board of Directors.

The composition of the committees of the fourth session of the Board of Directors is as follows:

- (1) the audit committee of the Company (the “**Audit Committee**”) comprises two independent non-executive Directors, namely Mr. Zhang Chun (chairman of the Audit Committee) and Dr. Shen Jingkang, and one non-executive Director, namely Mr. Tang Yi;
- (2) the nomination committee of the Company (the “**Nomination Committee**”) comprises two independent non-executive Directors, namely Dr. Feng Xiaoyuan (chairman of the Nomination Committee) and Dr. Yang Yue, and one executive Director, namely Mr. Xiong Jun;
- (3) the remuneration and appraisal committee of the Company (the “**Remuneration and Appraisal Committee**”) comprises three independent non-executive Directors, namely Mr. Zhang Chun (chairman of the Remuneration and Appraisal Committee), Dr. Feng Xiaoyuan and Dr. Yang Yue, and two executive Directors, namely Mr. Xiong Jun and Dr. Zou Jianjun; and
- (4) the strategic committee of the Company (the “**Strategic Committee**”) comprises three independent non-executive Directors, namely Mr. Zhang Chun, Dr. Meng Anming and Dr. Shen Jingkang, and two executive Directors, namely Mr. Xiong Jun (chairman of the Strategic Committee) and Dr. Zou Jianjun.

RETIREMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTORS

Retirement of non-executive Director

Dr. Feng Hui (“**Dr. Feng**”) has not stood for re-election as a non-executive Director and will retire from his position with effect from the date of the AGM.

Dr. Feng has confirmed that he has no disagreement with the Board of Directors, and there is no other matter that need to be brought to the attention of the shareholders of the Company (“**Shareholders**”) in relation to his retirement.

Retirement of independent non-executive Directors

Dr. Roy Steven Herbst (“**Dr. Herbst**”) and Mr. Qian Zhi (“**Mr. Qian**”) have not stood for re-election as independent non-executive Directors and will retire from their positions with effect from the date of the AGM.

Each of Dr. Herbst and Mr. Qian has confirmed that he has no disagreement with the Board of Directors, and there is no other matter that need to be brought to the attention of the Shareholders in relation to his retirement.

The Board of Directors would like to take this opportunity to express its sincere gratitude to Dr. Feng, Dr. Herbst and Mr. Qian for their contributions to the Company during their tenure of office.

ELECTION OF THE FOURTH SESSION OF THE BOARD OF SUPERVISORS AND APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

Election of the fourth session of the board of supervisors

The term of office of the third session of the board (the “**Board of Supervisors**”) of supervisors (the “**Supervisors**”) of the Company has expired on the conclusion of the AGM. The fourth session of the Board of Supervisors will consist of three Supervisors, comprising two non-employee representative Supervisors and one employee representative Supervisor and will have a term of office for three years with effect from the date of the AGM until the conclusion of the fourth session of the Board of Supervisors.

The two non-employee representative Supervisors, namely Ms. Kuang Hongyan and Ms. Wang Pingping, were elected to the fourth session of the Board of Supervisors at the AGM. Further details are set out in the Company’s poll results announcement dated 21 June 2024 and biographical details of the non-employee representative Supervisors are set out in the Company’s circular dated 30 May 2024.

At the Company’s employee representatives meeting held on 20 June 2024 (the “**Employee Representatives Meeting**”), the employee representatives resolved to appoint Ms. Huo Yilian (“**Ms. Huo**”) as an employee representative Supervisor of the fourth session of the Board of Supervisors.

At the first meeting of the fourth session of the Board of Supervisors held on 21 June 2024 (the “**Supervisors Meeting**”), Ms. Kuang Hongyan (“**Ms. Kuang**”) was elected as the chairman of the fourth session of the Board of Supervisors with a term of office for three years with effect from the date of the Supervisors Meeting until the conclusion of fourth session of the Board of Supervisors.

The biography of Ms. Huo is as follows:

Ms. Huo Yilan, aged 33, has been a purchasing manager and a deputy purchasing director of the Company successively since April 2021. She has been a supervisor of Shanghai Junshi Xihai Biotechnology Co., Ltd. since September 2021; the executive director and legal representative of Suzhou Junao Cancer Hospital Co., Ltd. since October 2022; and a supervisor of Wuxi Junshi Biomedical Technology Co., Ltd. and Wuxi Runmin Pharmaceutical Technology Co., Ltd. since December 2022.

Ms. Huo’s main experience prior to joining the Group includes: from November 2016 to May 2017, she served as a commercial operation coordinator at NBCUniversal Inc.; from April 2018 to June 2018, she served as a sales specialist in General Electric (China) Co., Ltd.; and from July 2018 to March 2021, she served as a sales specialist in ABB (China) Co., Ltd. Shanghai Office.

Ms. Huo obtained her bachelor’s degree in science from Pennsylvania State University, the United States in 2014 and her master’s degree in science from New York University, the United States in 2016.

As at the date of this announcement, save as disclosed above, Ms. Huo has confirmed that she: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did she hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company will enter into a service contract with Ms. Huo in relation to her appointment as an employee representative Supervisor. Ms. Huo will not receive any remuneration for serving as the employee representative Supervisor. Save as disclosed above, there are no other matters concerning the appointment of Ms. Huo that need to be brought to the attention of the shareholders of the Company nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

The Board of Directors and the Board of Supervisors would like to take this opportunity to extend a warm welcome to Ms. Huo for joining the Board of Supervisors.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 21 June 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, Dr. Shen Jingkan and Dr. Yang Yue as independent non-executive Directors.

* *For identification purpose only*